Antabio presents one of the most fascinating classification errors in the data ecosystem—a biopharmaceutical company fighting antibiotic resistance that the internet has mistakenly labeled as a fintech. With 27 employees and a mission to break antibacterial resistance, this company exists in a data blind spot that reveals more about digital classification failures than their actual business.

"When a biopharmaceutical company fighting antibiotic resistance gets classified as fintech, you know the data layer is broken."

The tech stack tells a story of abandonment or dormancy. WordPress with PHP and jQuery suggests a website that hasn't been updated in years, while the presence of PWA and lazy loading hints at ambitions that were never realized. The social profiles exist—Twitter and LinkedIn—yet generate no engagement. For a company with $2.5M in revenue, this digital silence is either strategic stealth or a missed opportunity of epic proportions.

• 27 employees with $2.5M revenue suggests a lean, focused operation
• Zero digital presence indicates either stealth mode or operational pivot
• Misclassification as fintech creates discovery barriers for biotech investors
• Key people include clinical project managers and lab technicians—true biopharma roles
• Website exists but generates no measurable traffic or engagement